Business
Rakovina Therapeutics Announces Debentureholder Approval of Debenture Extension, Expiry of Warrant Incentive Program
VANCOUVER, British Columbia, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (ȁ...
About this update from Rakovina Therapeutics Inc
[{"type":"text","content":"Rakovina Therapeutics Announces Debentureholder Approval of Debenture Extension, Expiry of Warrant Incentive Program\n\n\n\n VANCOUVER, British Columbia, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV)(FSE: 7JO0) a biopharmaceutical company advancing cancer therapies through AI-enabled drug discovery, announces that further to its news release dated June 30, 2025, and in accordance with the terms of a debenture indenture (the “\n \n Indenture\n \n ”) between the Company and Odyssey Trust Company as the debenture trustee (the “\n \n Debenture Trustee\n \n ”) dated May 29, 2023, governing the 12.0% convertible debentures of the Company in the aggregate principal amount of $1,454,000.00 (the \"\n \n Convertible Debentures\n \n \"), holders (each, a \"\n \n Debentureholder\n \n \") representing at least 66 2/3% of the outstanding principal of the Convertible Debentures have consented to the extension of the maturity date of the Convertible Debentures from November 29, 2025 to January 28, 2026 (the “\n \n Extension\n \n ”). The Extension was approved by way of a written consent dated November 28, 2025, in accordance with the terms of the Indenture. At this time, the Company has not proceeded with the amendments referenced in the June 30, 2025, news release.\n \n\n\n Amendment of Convertible Debentures\n \n\n\n The Company proposes to execute a supplemental indenture with the Debenture Trustee amending the terms of the Indenture to reflect the Extension. All other terms will remain the same and the Convertible Debentures will continue to bear interest at a rate of 12.0% during the Extension. The Extension remains subject to the approval of the TSX Venture Exchange (the “\n \n Exchange\n \n ”).\n \n\n\n Related Party Disclosure\n \n\n\n Certain directors of the Company, as a group, beneficially own, control or direct, directly, or indirectly, approximately $100,000 principal amount of the Convertible Debentures, representing approximately 6.9% of the outstanding principal amount of the Convertible Debentures. Participation by such persons in the Extension constituted a \"related party transaction\" as defined under Multilateral Instrument 61-101 -\n \n Protection of Minority Security Holders in Spe...